Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 4, 2015, Pages 394-402

  Florian, J ^a   Mishra, P ^a   Arya, V ^a   Harrington, P ^a   Connelly, S ^a   Reynolds, K S ^a   Sinha, V ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL DRUG; INTERFERON; UNCLASSIFIED DRUG;

ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS C; DRUG APPROVAL; DRUG INTERACTION; DRUG RESPONSE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MATHEMATICAL MODEL; MIXED INFECTION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VIRUS GENE; ANIMAL; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; PATHOGENICITY; RISK ASSESSMENT; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG DISCOVERY; DRUG INTERACTIONS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84952760763     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.185     Document Type: Article

References (55)

1. Mohd Hanafiah, K., Groeger, J., Flaxman, A.D. & Wiersma, S.T. Epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57(4), 1333-1342 (2013).
2. Armstrong, G.L. et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann. Intern. Med. 144(10), 705-714 (2006).
3. WHO. Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 2 July 2015.
4. Ly, K.N. et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann. Intern. Med. 156(4), 271-278 (2012).
5. Wong, J.B., McQuillan, G.M., McHutchison, J.G. & Poynard, T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health 90(10), 1562-1569 (2000).
6. Smith, B.D. et al. Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. Am. J. Public Health 104(3), 474-481, (2014).
7. Davis, G.L., Alter, M.J., El-Seraq, H., Poynard, T. & Jennings, L.W. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138(2), 513-5121 (2010).
8. Scheel, T.K. & Rice, C.M. Understanding the hepatitis C virus life cycles paves the way for highly effective therapies. Nat. Med. 19(7), 837-849 (2013).
9. Ghany, M.G., Strader, D.B., Thomas, D.L., Seeff, L.B. & American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49(4), 1335-1374 (2011).
10. Ghany, M.G., Nelson, D.R., Strader, D.B., Thomas, D.L., Seeff, L.B. & American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4), 1433-1444 (2011).
11. American Association for the Study of Liver Diseases (AASLD), and Infectious Diseases Society of America (IDSA), in collaboration with International Antiviral Society-USA (IAS-USA). Recommendations for testing, managing, and treating hepatitis C 2014. http://www. hcvguidelines.org.
12. VICTRELIS (boceprevir) capsules, for oral use. US Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/202258s014lbl.pdf.
13. INCIVEK (telaprevir) tablets, for oral use. US Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/201917s012lbl.pdf.
14. OLYSIO (simeprevir) capsules, for oral use. US Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205123s002lbledt.pdf.
15. SOVALDI (sofosbuvir) tablets, for oral use. US Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204671s001lbl.pdf.
16. HARVONI (ledipasvir and sofosbuvir) tablets, for oral use. US Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/205834s000lbl.pdf.
17. VIEKIRA-PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use. US Prescribing Information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/206619lbl.pdf.
18. Gower, E. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J. Hepatol 61(suppl. 1), S45-S57 (2014).
19. Messina, J.P. et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61(1), 77-87 (2015).
20. Backus, L.I. et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin. Gastroenterol. Hepatol. 9(6), 509-516 (2011).
21. Singal, A.G., Volk, M.L., Jensen, D., Di Bisceglie, A.M. & Schoenfeld, P.S. A sustained viral response is associated with reduced liver related morbidity and mortality in patients with hepatitis C virus. Clin. Gastroenterol. Hepatol. 8(3), 280-288 (2010).
22. van der Meer, A.J. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308(24), 2584-2593 (2012).
23. Veldt, B.J. et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med. 147 (10), 677-684 (2007).
24. Mishra, P., Murray, J. & Birnkrant, D. Direct-acting antiviral drug approvals for treatment of chronic hepatitis C virus infection: scientific and regulatory approaches to clinical trial designs. Hepatology (2015); e-pub ahead of print (doi:10.1002/hep.27880).
25. Chen, J. et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 144(7), 1450-1455 (2013).
26. Sherman, K.E. et al. Development of novel agents for the treatment of chronic hepatitis C infection: summary of the FDA Antiviral Products Advisory Committee recommendations. Hepatology 46(6), 2014-2020 (2007).
27. Antiviral Drugs Advisory Committee Meeting (October 19-20, 2006) Transcripts. http://www.fda.gov/ohrms/dockets/ac/cder06. html#AntiviralDrugs. Accessed 8 August 2014.
28. Guidance for Industry Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Gui-dances/UCM225333.pdf. Accessed 8 August 2014.
29. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 8 January 2015.
30. Ge, D., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
31. Florian, J. et al. Boceprevir dosing for late responders and null responders: the role of bridging data between treatment-na€ive and-experienced subjects. Hepatology 57 (3), 903-907 (2013).
32. Mishra, P. et al. FDA perspective on sofosbuvir therapy for patients with chronic hepatitis c virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin. Gastroenterology 147(6), 1196-1200 (2014).
33. Afdhal, N. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. NEJM 370(16), 1483-1493 (2014).
34. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M. & Ho, D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586 (1996).
35. Neumann, A.U. et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282(5386), 103-107 (1998).
36. Neumann, A.U. et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182(1), 28-35 (2000).
37. Rong, L., Dahari, H., Ribeiro, R.M. & Perelson, A.S. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci. Transl. Med. 2(30), 30ra32 (2010).
38. Adiwijaya, B.S. et al. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Antivir. Ther. 14(4), 591-595 (2009).
39. Dahari, H., Ribeiro, R.M., Rice, C.M. & Perelson, A.S. Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J. Virol. 81(2), 750-760 (2007).
40. Dahari, H. et al. A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease. Gastroenterology 136(4), 1402-1409 (2009).
41. Soriano, et al. Drug intercations with new hepatitis C oral drugs. Exp. Opin. Drug Metab. Toxicol. 11(3), 1-9 (2015).
42. Kiser, J.J. & Flexner, C. Direct-acting antiviral agents for hepatitis C virus infection. Annu. Rev. Pharmacol. Toxicol. 53, 427-449 (2013)
43. Centers for Disease Control and Prevention. Viral Hepatitis-CDC Recommendations for Specific Populations and Settings. http://www.cdc.gov/hepatitis/Populations/hiv.htm. Accessed 5 May 2015.
44. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed 6 May 2015.
45. Graham, C.S. et al. Influence of human immunodeficiency virus nfection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 33(4), 562-569 (2001).
46. Chen, J.Y., Feeney, E.R. & Chung, R.T. HCV and HIV co-infection: mechanisms and management. Nat. Rev. Gastroenterol. Hepatol. 11(6), 362-371 (2014).
47. Naggie, S. & Sulkowski, M.S. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 142, 1324-1334 (2012).
48. Karageorgopoulos, D.E., El-Sherif, O., Bhagani, S. & Khoo, S.H. Drug nteractions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection. Curr. Opin. Infect. Dis. 27, 36-45 (2014).
49. Schiff, J., Cole, E. & Cantarovich, M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin. J. Am. Soc. Nephrol. 2(2), 374-384 (2007).
50. Hezode, C. et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicenter cohort of the French Early Access Programme. J. Heptaol. 59, 434-441 (2013).
51. Gordon, S.C. et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. J Hepatol. 62(2), 286-293 (2015).
52. Luetkemeyer, A.F. &Wyles. D.L. CROI 2015: Highlights of viral hepatitis therapy. Top. Antivir. Med. 23(10), 66-76 (2015).
53. Stine, J.G. et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig. Dis. Sci. 60(4), 1031-1035 (2015).
54. FDA Drug Safety Communication: FDA warns of serious slowing of the heart rate when antiarrhythmic drug amiodarone is used with hepatitis C treatments containing sofosbuvir (Harvoni) or Solvaldi in combination with another Direct Acting Antiviral drug, (March 24, 2014) http://www.fda.gov/Drugs/DrugSafety/ucm439484.htm. Accessed 5 July 2015.
55. HCV-TARGET-Hepatitis C Therapeutic Registry and Research Network. http://www.hcvtarget.org/index.php/news/fda-news-release-aug-29-2013. Accessed 8 August 2014.